Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01122615 · ClinicalTrials.gov registry record · Phase 1
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01122615: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01122615 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01122615, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of sunitinib and temsirolimus that can be given to patients with metastatic kidney cancer.
Interventions
- DRUG Sunitinib
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-05 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01122615
The ClinicalTrials.gov registry entry for NCT01122615 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sunitinib is the first listed.
NCT01122615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01122615 about?
NCT01122615 is a clinical study titled "Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)". The goal of this clinical research study is to find the highest tolerable dose of the combination of sunitinib and temsirolimus that can be given to patients with metastatic kidney cancer.
What is the current status of trial NCT01122615?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2010-05. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01122615?
The interventions under investigation include: Sunitinib (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01122615?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.